A pilot open-label trial of citalopram for restless activity and aberrant motor behaviors in Alzheimer disease.

Objective: In a prospective, open-label pilot study in probable-Alzheimer disease (AD) outpatients, the authors investigated the efficacy of citalopram to reduce restless activity and aberrant motor behaviors.

Methods: Nineteen subjects were evaluated with Neuropsychiatric Inventory subscale and total scores.

Results: There was a significant decline in aberrant motor behaviors and overall behavior problems at 4, 8, and 12 weeks.